JP2023527354A5 - - Google Patents
Info
- Publication number
- JP2023527354A5 JP2023527354A5 JP2022572560A JP2022572560A JP2023527354A5 JP 2023527354 A5 JP2023527354 A5 JP 2023527354A5 JP 2022572560 A JP2022572560 A JP 2022572560A JP 2022572560 A JP2022572560 A JP 2022572560A JP 2023527354 A5 JP2023527354 A5 JP 2023527354A5
- Authority
- JP
- Japan
- Prior art keywords
- aav
- manipulated
- item
- guide rna
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030166P | 2020-05-26 | 2020-05-26 | |
| US63/030,166 | 2020-05-26 | ||
| US202063112329P | 2020-11-11 | 2020-11-11 | |
| US63/112,329 | 2020-11-11 | ||
| US202063119921P | 2020-12-01 | 2020-12-01 | |
| US63/119,921 | 2020-12-01 | ||
| US202163153175P | 2021-02-24 | 2021-02-24 | |
| US63/153,175 | 2021-02-24 | ||
| US202163178059P | 2021-04-22 | 2021-04-22 | |
| US63/178,059 | 2021-04-22 | ||
| PCT/US2021/034323 WO2021242903A2 (en) | 2020-05-26 | 2021-05-26 | Compositions and methods for modifying target rnas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527354A JP2023527354A (ja) | 2023-06-28 |
| JP2023527354A5 true JP2023527354A5 (cg-RX-API-DMAC7.html) | 2024-06-03 |
Family
ID=76502872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572560A Pending JP2023527354A (ja) | 2020-05-26 | 2021-05-26 | 標的ｒｎａを修飾するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230193279A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4158024A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023527354A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021280283A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177380A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021242903A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| WO2023278436A1 (en) * | 2021-06-29 | 2023-01-05 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides |
| CA3223109A1 (en) * | 2021-06-29 | 2023-01-05 | Richard Thomas SULLIVAN | Engineered guide rnas and polynucleotides |
| AU2022337146A1 (en) | 2021-09-03 | 2024-03-14 | Tacit Therapeutics, Inc. | Rna editing via recruitment of spliceosome components |
| EP4423274A2 (en) * | 2021-10-26 | 2024-09-04 | Shape Therapeutics Inc. | Rna-editing compositions and methods of use |
| EP4441219A2 (en) * | 2021-12-01 | 2024-10-09 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides for rna editing targeting lrrk2 |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| AU2023390632A1 (en) | 2022-12-09 | 2025-07-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2024137991A2 (en) * | 2022-12-23 | 2024-06-27 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| EP4689110A1 (en) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| EP4691475A1 (en) * | 2023-03-31 | 2026-02-11 | Recorna (Guangzhou) Biotechnology Co., Ltd. | Sequence for forming editing substrate together with rna editing target site |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| TW202523678A (zh) * | 2023-12-14 | 2025-06-16 | 國立臺灣大學 | ＣＲＩＳＰＲＩ標靶α－突觸核蛋白 |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3234134B1 (en) * | 2014-12-17 | 2020-05-27 | ProQR Therapeutics II B.V. | Targeted rna editing |
| US10370667B2 (en) * | 2015-11-18 | 2019-08-06 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease |
| EP3571300A1 (en) * | 2017-01-19 | 2019-11-27 | ProQR Therapeutics II B.V. | Oligonucleotide complexes for use in rna editing |
| US11866697B2 (en) * | 2017-05-18 | 2024-01-09 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| WO2019084062A1 (en) * | 2017-10-23 | 2019-05-02 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION |
-
2021
- 2021-05-26 CA CA3177380A patent/CA3177380A1/en active Pending
- 2021-05-26 US US17/925,871 patent/US20230193279A1/en active Pending
- 2021-05-26 WO PCT/US2021/034323 patent/WO2021242903A2/en not_active Ceased
- 2021-05-26 EP EP21733326.9A patent/EP4158024A2/en active Pending
- 2021-05-26 AU AU2021280283A patent/AU2021280283A1/en active Pending
- 2021-05-26 JP JP2022572560A patent/JP2023527354A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023527354A5 (cg-RX-API-DMAC7.html) | ||
| US20230203483A1 (en) | Compositions and Methods Using SNRNA Components | |
| JP2025148448A (ja) | アデノ随伴ウイルスベクター変種 | |
| JP2023504314A5 (cg-RX-API-DMAC7.html) | ||
| CA3177380A1 (en) | Compositions and methods for modifying target rnas | |
| GB2590880A (en) | RNA and DNA base editing via engineered ADAR recruitment | |
| CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
| WO2023154693A1 (en) | Aav capsid variants and uses thereof | |
| JP2013531471A5 (cg-RX-API-DMAC7.html) | ||
| CN114450031A (zh) | 靶向rna的敲低和替代组合物及使用方法 | |
| WO2015157070A2 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
| CN114480440A (zh) | 靶向中枢神经系统的aav载体 | |
| JP2021522836A5 (cg-RX-API-DMAC7.html) | ||
| JP2023551873A (ja) | Ｃａｇリピート病を処置するためのｒｎａ標的化組成物および方法 | |
| US20220175960A1 (en) | Fasl immunomodulatory gene therapy compositions and methods for use | |
| JP2025507958A (ja) | 操作された核内低分子ＲＮＡ（ｓｎＲＮＡ）を含む組成物および方法 | |
| US20220380798A1 (en) | AAV Expression Cassette and AAV Vectors Comprising the Same | |
| US20250215453A1 (en) | Aav capsid variants and uses thereof | |
| WO2025038430A1 (en) | Aav capsid variants and uses thereof | |
| JP2021534794A (ja) | 変異型ｇａｒｓタンパク質の発現を阻害するための生成物および方法 | |
| JP2022522166A5 (cg-RX-API-DMAC7.html) | ||
| JP2023541444A5 (cg-RX-API-DMAC7.html) | ||
| JP2025512061A5 (cg-RX-API-DMAC7.html) | ||
| CN117320741A (zh) | 用于治疗cag重复疾病的靶向rna的组合物和方法 | |
| JP2022508835A5 (cg-RX-API-DMAC7.html) |